Masonic Cancer Center, University of Minnesota: Myelodysplastic Syndromes trials
The registry lists 38 Myelodysplastic Syndromes studies with Masonic Cancer Center, University of Minnesota as lead sponsor. 4 are open to participants now and 21 have results posted.
Phase 1 14Phase 2 26No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological DiseasesRecruitingNCT07493538Phase 2
- HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AMLRecruitingNCT06594445Phase 1
- Allo HSCT Using RIC and PTCy for Hematological DiseasesRecruitingNCT05805605Phase 2
- Alpha/Beta TCD HCT in Patients With Inherited BMF DisordersRecruitingNCT03579875Phase 2
- PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC TransplantationCompletedNCT05120570Phase 1/2Results posted
- Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDSCompletedNCT04055844Phase 2Results posted
- Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDSCompletedNCT03417154Phase 2Results posted
- Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme MalignanciesTerminatedNCT02991898Phase 2Results posted
- Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCTCompletedNCT02989844Phase 2Results posted
- UCB Transplant for Hematological Diseases Using a Non Myeloablative PrepCompletedNCT02722668Phase 2Results posted
- IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCTCompletedNCT01885897Phase 1/2Results posted
- Busulfan and Cyclophosphamide Followed By ALLO BMTTerminatedNCT01685411Not applicableResults posted
- Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic SyndromesCompletedNCT01593670Phase 2Results posted
- NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid DiseasesCompletedNCT01370213Phase 2Results posted
- Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic CancerTerminatedNCT00963872Phase 1/2Results posted
- Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid LeukemiaTerminatedNCT00818649Phase 2Results posted
- Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell TransplantTerminatedNCT00602446Phase 2Results posted
- Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other DiseaseTerminatedNCT00392782Phase 2Results posted
- Hematopoietic Stem Cell Transplantation in the Treatment of Infant LeukemiaCompletedNCT00357565Phase 2Results posted
- Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.TerminatedNCT00354172Phase 2Results posted
- Myeloablative Umbilical Cord Blood Transplantation in Hematological DiseasesCompletedNCT00309842Phase 2Results posted
- Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood TransplantCompletedNCT00305682Phase 2Results posted
- Allogeneic Bone Marrow Transplantation Using Less Intensive TherapyTerminatedNCT00303719Phase 2Results posted
- Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic CancerTerminatedNCT00295880Phase 1/2Results posted
- Post Transplant Donor Lymphocyte InfusionTerminatedNCT00167180Phase 2Results posted
- QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AMLWithdrawnNCT03365661Phase 2
- Allo HSCT Using RIC for Hematological DiseasesCompletedNCT02661035Phase 2
- Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell TransplantationCompletedNCT01634217Phase 1
- Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)CompletedNCT01385423Phase 1
- AHN-12 Biodistribution in Advanced LeukemiaTerminatedNCT01207076Phase 1
- Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantTerminatedNCT00725062Phase 1
- Total Marrow Irradiation for Refractory Acute LeukemiaCompletedNCT00686556Phase 1
- Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced LeukemiaTerminatedNCT00618696Phase 1
- T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic CancerCompletedNCT00602693Phase 1
- Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic DiseasesTerminatedNCT00376519Phase 1
- Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney CancerCompletedNCT00365287Phase 1/2
- Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic CancerCompletedNCT00290641Not applicable
- Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerTerminatedNCT00290628Not applicable